Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis

被引：0
|
作者：
Pui San Tan
Pedro Aguiar
Benjamin Haaland
Gilberto Lopes
机构：
[1] University of Oxford,Nuffield Department of Primary Care Health Sciences
[2] Clinical Oncology Sector,Population Health Sciences and Huntsman Cancer Institute
[3] Faculdade de Medicina do ABC,Sylvester Comprehensive Cancer Center
[4] University of Utah,undefined
[5] University of Miami,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：516 / 523
页数：7
相关论文
共 50 条
  • [1] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Tan, Pui San
    Aguiar Jr, Pedro
    Haaland, Benjamin
    Lopes, Gilberto
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
  • [2] Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population
    Gupta, Alok
    Hussain, Shaik Maheboob
    Sonthwal, Neha
    Chaturvedi, Harit
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (02) : 389 - 392
  • [3] Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
    Roy, Soumyajit
    Sayyid, Rashid
    Saad, Fred
    Sun, Yilun
    Lajkosz, Katherine
    Ong, Michael
    Klaassen, Zachary
    Malone, Shawn
    Spratt, Daniel E.
    Wallis, Christopher J. D.
    Morgan, Scott C.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 494 - 502
  • [4] Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
    Tucci, Marcello
    Bertaglia, Valentina
    Vignani, Francesca
    Buttigliero, Consuelo
    Fiori, Cristian
    Porpiglia, Francesco
    Scagliotti, Giorgio Vittorio
    Di Maio, Massimo
    EUROPEAN UROLOGY, 2016, 69 (04) : 563 - 573
  • [5] Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (mHSPC): An updated network meta-analysis and cost minimization analysis in China.
    Hu, Xin
    Yao, Xingxing
    Li, Chaoyun
    Liu, Yanjun
    Xiong, Tengbin
    Qu, Shuli
    Wang, Jianye
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
    Maiorano, B. A.
    De Giorgi, U.
    Roviello, G.
    Messina, C.
    Altavilla, A.
    Cattrini, C.
    Mennitto, A.
    Maiello, E.
    Di Maio, M.
    ESMO OPEN, 2022, 7 (05)
  • [7] Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis
    Yanagisawa, Takafumi
    Rajwa, Pawel
    Thibault, Constance
    Gandaglia, Giorgio
    Mori, Keiichiro
    Kawada, Tatsushi
    Fukuokaya, Wataru
    Shim, Sung Ryul
    Mostafaei, Hadi
    Motlagh, Reza Sari
    Quhal, Fahad
    Laukhtina, Ekaterina
    Pallauf, Maximilian
    Pradere, Benjamin
    Kimura, Takahiro
    Egawa, Shin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2022, 82 (06) : 584 - 598
  • [8] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
    Kalebasty, Arash Rezazadeh
    Hammerer, Peter
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Mathew
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
  • [9] Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
    Rydzewska, Larysa H. M.
    Burdett, Sarah
    Vale, Claire L.
    Clarke, Noel W.
    Fizazi, Karim
    Kheoh, Thian
    Mason, Malcolm D.
    Miladinovic, Branko
    James, Nicholas D.
    Parmar, Mahesh K. B.
    Spears, Melissa R.
    Sweeney, Christopher J.
    Sydes, Matthew R.
    NamPhuong Tran
    Tierney, Jayne F.
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 88 - 101
  • [10] Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy
    Kassem, Loay
    Shohdy, Kyrillus S.
    Abdel-Rahman, Omar
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 903 - 910
12345